Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 5/20 | 0.74 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.74 |
| ▸ | BTK | Q06187 | 4/20 | 0.74 |
| ▸ | JAK3 | P52333 | 7/20 | 0.71 |
| ▸ | EGFR | P00533 | 5/20 | 0.71 |
| ▸ | JAK2 | O60674 | 1/20 | 0.71 |
| ▸ | BLK | P51451 | 1/20 | 0.71 |
| ▸ | BMX | P51813 | 1/20 | 0.71 |
| ▸ | SRC | P12931 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.66 |
| ▸ | FLT3 | P36888 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93523 | 1.00 | MAP3K7 (0.74) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL30854787 | 1.00 | MAP3K7 (0.74) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL10127876 | 0.88 | JAK3 (0.80) | BTKJAK3EGFRJAK2BLK | |
| SCHEMBL28980968 | 0.87 | BTK (0.80) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL31684778 | 0.87 | BTK (0.80) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL22604799 | 0.85 | BTK (0.62) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL10127962 | 0.85 | BTK (1.00) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL22604617 | 0.85 | EGFR (0.59) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL14914404 | 0.84 | EGFR (0.70) | MAP3K7MAP2K1BTKJAK3EGFR | |
| SCHEMBL28980965 | 0.83 | MAP3K7 (0.81) | MAP3K7MAP2K1BTKJAK3EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 990 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595297-B2 | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors | IN3BIO LTD. (BM) | 2026-04-07 | — | — | US | claimed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | claimed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | claimed |
| WO-2025137424-A1 | SOLID FORMS OF AN ERBB INHIBITOR | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| US-20240425492-A1 | POLYMORPHS AS ERBB INHIBITORS | BLACK DIAMOND THERAPEUTICS, INC. | 2024-12-26 | — | — | US | claimed |
| CN-119110799-A | Polymorphs as ERBB inhibitors | 黑钻治疗公司 | 2024-12-10 | — | — | CN | claimed |
| EP-4405350-A1 | POLYMORPHS AS ERBB INHIBITORS | Black Diamond Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| US-20240245634-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | UNITED STATES GOVERNMENT | 2024-07-25 | — | — | US | claimed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | claimed |
| EP-4330224-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | City of Hope (US) | 2024-03-06 | — | — | EP | claimed |
| EP-4106879-A1 | IDENTIFICATION OF AN EGFR-BIN3 PATHWAY THAT ACTIVELY SUPPRESSES INVASION AND REDUCES TUMOR SIZE IN GLIOBLASTOMA | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-12-28 | — | — | EP | claimed |
| EP-4106793-A1 | EGFR INHIBITION TRIGGERS AN ADAPTIVE RESPONSE BY CO-OPTING ANTIVIRAL SIGNALING PATHWAYS IN LUNG CANCER | United States Government as Represented by The Department of Veterans Affairs (US) | 2022-12-28 | — | — | EP | claimed |
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-25 | — | — | US | claimed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| US-20220218682-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-14 | — | — | US | claimed |
| US-20220211706-A1 | Methods and Compositions for Treating Cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2022-07-07 | — | — | US | claimed |
| EP-4011376-A2 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-15 | — | — | EP | claimed |
| US-11285154-B2 | Methods and compositions for treating cancer | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2022-03-29 | — | — | US | claimed |
| EP-3965896-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The United States Government as Represented by the Department of Veterans Affairs (US) | 2022-03-16 | — | — | EP | claimed |
| US-20220041704-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS | IN3BIO LTD. (BM) | 2022-02-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240425492-A1 | POLYMORPHS AS ERBB INHIBITORS | ERBB4, ERBB2, ERBB3 | MAP3K7 218/4885MAP2K1 417/4885BTK 746/4885 |
| US-12595297-B2 | Methods and compositions for inhibition of EGF/EGFR pathway in combination with tyrosine kinase inhibitors | EGFR, ERBB2, ERBB3 | MAP3K7 134/4885MAP2K1 95/4885BTK 99/4885 |
| US-20240245634-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | PCNA, MKI67, EGFR | MAP3K7 146/4885MAP2K1 71/4885BTK 647/4885 |
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ROS1, ALK, PTK2 | MAP3K7 84/4885MAP2K1 393/4885BTK 46/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | MAP3K7 2806/4885MAP2K1 2427/4885BTK 2184/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | MAP3K7 3479/4885MAP2K1 4459/4885BTK 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.